List of Excipients in Branded Drug FLUTICASONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	FLUTICASONE FUROATE AND VILANTEROL	fluticasone furoate and vilanterol	66993-135	LACTOSE MONOHYDRATE	2029-08-26
Prasco Laboratories	FLUTICASONE FUROATE AND VILANTEROL	fluticasone furoate and vilanterol	66993-135	MAGNESIUM STEARATE	2029-08-26
Prasco Laboratories	FLUTICASONE FUROATE ELLIPTA	fluticasone furoate	66993-166	LACTOSE MONOHYDRATE	2026-03-01
Fougera Pharmaceuticals Inc	FLUTICASONE PROPIONATE	fluticasone propionate	0168-0434	CETETH-20

Generic Drugs Containing FLUTICASONE

Company	Ingredient	NDC	Excipient
Unit Dose Services	fluticasone propionate	50436-2640	ANHYDROUS DEXTROSE
Unit Dose Services	fluticasone propionate	50436-2640	BENZALKONIUM CHLORIDE
Unit Dose Services	fluticasone propionate	50436-2640	CARBOXYMETHYLCELLULOSE SODIUM
Unit Dose Services	fluticasone propionate	50436-2640	PHENYLETHYL ALCOHOL

What are the Most Frequently-Used Excipients in FLUTICASONE?

# Of NDCs	Excipient
7	ANHYDROUS DEXTROSE
8	BENZALKONIUM CHLORIDE
8	CARBOXYMETHYLCELLULOSE SODIUM
1	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Fluticasone

Last updated: February 25, 2026

Fluticasone, a corticosteroid used primarily for respiratory conditions such as asthma and allergic rhinitis, holds significant market value. Its formulation complexity influences both drug stability and delivery. Effective excipient selection is critical to optimize bioavailability, shelf life, and patient compliance. The strategic use of excipients enhances product performance and can open new commercial avenues.

What Are the Key Excipients in Fluticasone Formulations?

Fluticasone formulations typically contain several excipients addressing drug stability, delivery, and patient acceptability:

• Propellants and solvents: For inhalation sprays, hydrofluoroalkanes (HFAs) like HFA-134a are standard. These are inert, stable, and contribute to aerosol performance.
• Absorption enhancers: Surfactants facilitate drug penetration through mucosal tissues in inhalers.
• Preservatives: Chlorobutanol or benzalkonium chloride maintain microbial stability, especially in aqueous nasal sprays.
• Stabilizers: Antioxidants such as ascorbic acid prevent oxidative degradation of fluticasone.
• Bulking agents and fillers: Lactose is common in dry powder inhalers (DPIs), aiding powder flow and dose uniformity.

How Does Excipients Strategy Impact Fluticasone Product Development?

1. Enhanced Stability: Choosing antioxidants and stabilizers prolongs shelf life. For example, including antioxidants like vitamin E during manufacturing can protect fluticasone from oxidation.

2. Optimized Delivery: Surfactants and propellants improve aerosolization and mucosal penetration, increasing bioavailability.

3. Patient Compatibility: Excipient selection affects tolerability; lactose in DPIs excludes lactose-sensitive populations, prompting alternate formulations.

4. Manufacturing Efficiency: Excipients influence processability, powder flow, and dose uniformity, impacting production costs and scalability.

Commercial Opportunities from Excipient Innovation

1. Development of Non-Lactose Based DPIs

Lactose intolerance limits DPI use among some populations. Formulating with alternative carriers like mannitol or coarse glucose improves market penetration.

2. Proprietary Stabilization Systems

Patented antioxidant or preservative systems can differentiate products. These include novel antioxidants that extend shelf life or reduce cold chain dependence. Such innovations command premium pricing.

3. Moisture-Resistant Formulations

In humid climates, moisture-sensitive excipients like lactose need protection. Developing moisture-resistant coatings or alternative excipients creates opportunities for global commercialization.

4. Next-Generation Inhaler Formulations

Incorporating smart excipients that enhance drug absorption or control release can improve efficacy. Examples incorporate biodegradable polymers or bioadhesive agents.

5. Nasal Spray Vehicles

Advances in excipient-based mucoadhesive agents improve nasal retention time, broadening indications and increasing market share in allergic rhinitis therapies.

Market Size and Revenue Implication

The global inhaled corticosteroids (ICS) market, including fluticasone, was valued at approximately USD 5 billion in 2022, with a Compound Annual Growth Rate (CAGR) of 4.7% projected through 2030 (Research and Markets, 2023).

Excipients contribute 10–15% to manufacturing costs, but strategic selection and innovation can yield higher margins via product differentiation.

Regulatory and Patent Landscape

Innovations in excipient compositions can support new patent filings, extending exclusivity periods. Regulatory agencies like the FDA evaluate excipient safety and manufacturing processes; novel excipients or delivery systems may require pre-market approval.

Strategic Recommendations

• Focus on developing allergen-free or lactose-free formulations.
• Invest in proprietary stabilization excipients to enhance product shelf life.
• Explore moisture-resistant formulations for emerging markets.
• Leverage excipient innovation to extend patent exclusivity.
• Monitor regulatory changes impacting excipient approval pathways.

Key Takeaways

• Excipient choice directly influences fluticasone's formulation stability, delivery, and patient tolerability.
• Innovation in excipient systems can unlock premium pricing and competitive advantages.
• Addressing regional needs through excipient adaptation broadens market reach.
• Regulatory approval for new excipients or formulations reinforces market exclusivity.
• The overall market value underscores the leveraging potential of formulation strategies.

FAQs

Q1: What are common excipients in fluticasone inhalers?
A: Propellants (HFA-134a), surfactants, preservatives (benzalkonium chloride), stabilizers (ascorbic acid), and carriers like lactose.

Q2: How does excipient choice affect drug stability?
A: Stabilizers like antioxidants prevent oxidation; moisture barriers prevent hydrolytic degradation.

Q3: Can excipient innovation extend product patent life?
A: Yes, novel excipient formulations can support patent filings, delaying generic competition.

Q4: What are the challenges in replacing lactose in DPI formulations?
A: Ensuring consistent powder flow, maintaining dose uniformity, and avoiding allergenic reactions.

Q5: How does moisture sensitivity influence formulation strategy?
A: Moisture-sensitive excipients necessitate protective coatings or alternative carriers to ensure product integrity.

---

References

1. Research and Markets. (2023). Global inhaled corticosteroids market analysis.
2. U.S. Food and Drug Administration. (2021). Guidance for industry: Excipients in drug products and formulations.